Background and Purpose: We recently demonstrated that pretreatment with the synthetic glucocorticoid
(n=15) hours of hypoxia-ischemia. Additional animals (n=20) were perfusion-fixed 3 days after hypoxia-ischemia. The area of cerebral pathological changes was measured from hematoxylin and eosin-stained coronal sections taken at three different levels.
Results: Pathological outcome differed between groups. In vehicle-treated rats, sections from anterior, mid, and posterior portions of the cerebrum all had extensive infarction or cellular necrosis ipsilateral to the occlusion (mean areas of damage were 62.6+10%, 70.29%No, and 54.2+8%, respectively). However, in dexamethasone-treated animals, brain damage in sections at corresponding levels was minimal (0%1, 1 .6±2%, and 1.5±1%, respectively; p<O.0002). In contrast to the pathological results, cerebral blood flow was equivalent in the dexamethasone-and vehicle-treated groups. After either 2 or 3 hours of hypoxia, cerebral blood flow was reduced 60-80%o ipsilateral to the carotid artery occlusion in animals treated with either vehicle or dexamethasone.
Conclusions: Despite ischemic levels of cerebral blood flow, pretreatment with dexamethasone prevents cerebral damage in elevations in perfusion pressure). Indeed, high-dose dexamethasone therapy has been associated with hypertension and bradycardia in human infants.4-6 In addition, high doses of glucocorticoids have also been reported to reduce cerebrovascular resistance and increase blood flow in adult animals.78 We presently investigate whether dexamethasone provides neuroprotection via an improvement in local cerebral perfusion ipsilateral to the carotid artery occlusion during hypoxia.
Materials and Methods
Immature Wistar rats from six different litters that had been bred in the animal facility were used. The rat pups were randomly treated with either vehicle or 0.1 mg/kg i.p. dexamethasone phosphate (Sabex Inc., Montreal, Canada) on the sixth day of life 24 hours before hypoxia-ischemia. All animals underwent cerebral hypoxia-ischemia and were grouped randomly for the measurement of local cerebral blood flow (n =32) or the examination of pathological damage (n=20). The rats were weighed on the day of treatment and on the day of hypoxia-ischemia. Blood glucose was measured in a separate group of animals using a drop of blood from the tail vein and glucose oxidase reagent strips (Chemstrip bG, Boehringer Mannheim, Mannheim, FRG).
The rats were subjected to hypoxia-ischemia on the seventh day of life as described in detail previously.' Briefly, they were prepared for surgery by infiltrating the incision site with 2% lidocaine and injecting 0.1 ml i.p. saline. The rats were anesthetized with halothane (3-4% for induction, 1/2-1% for maintenance), and the right carotid artery was isolated and ligated with 5-0 silk suture. A 3-hour recovery period with the dam was followed by 3 hours in a hypoxic chamber (8% O2/92% N2 at 37°C). This consistently produces neuronal damage with infarction of the striatum, thalamus, hippocampus, and overlying cortex ipsilateral to the ligation.1 '9-11 The technique used to measure local cerebral blood flow in 7-day old rats is similar to that developed by Lyons et al12 and uses methods based on those established for adult rats.13 Briefly, 0.1 ml s.c. saline containing 7 ,uCi of the blood flow tracer 4-[N-methyl-'4C]iodoantipyrine (New England Nuclear-Du Pont, Mississauga, Canada) was injected in the back. The tracer was gradually absorbed into the systemic circulation, and 2 minutes after injection the animal was decapitated and a blood sample was collected from the severed trunk vessels. The concentration of tracer in the blood sample was determined using liquid scintillation counting methods.14 The brain was removed, frozen, and processed for autoradiography as described elsewhere.'4 Briefly, brain sections 20 gm thick were cut semiserially in a cryostat, mounted on coverslips, and dried on a hot plate. Autoradiograms were obtained by applying x-ray film (OMC1, Kodak, Rochester, N.Y.) to the sections and a series of 16 calibrated standards (0-1,260 nCi/g).
Calculation of local cerebral blood flow according to the theory for the measurement of flow with a freely diffusible tracer15 requires knowledge of the final concentration of tracer in the tissue, the arterial input curve, and the partition coefficient. Local tissue concentrations of tracer were determined from the average of unilateral measurements from six sections. Gray levels were converted to tissue concentrations by using the gray levels of the standards and software provided with a microcomputer-based image analysis system (MCID, Imaging Research Inc., St. Catharines, Canada). The shape of the blood saturation curve, as tracer was absorbed systemically, was determined using 22 additional rats (either litter mates or pups of similar weights from other litters). These animals were treated with vehicle or dexamethasone and killed during hypoxia 0, 40, 60, 80, 100, 110, 120, or 130 seconds after subcutaneous injection of the tracer. A plot of kill time versus concentration of tracer in the blood provided an input curve that was similar to that of Lyons et al12 and was equivalent in vehicle-and dexamethasone-treated rats. For each blood flow experiment, the blood concentration at the kill time was used to estimate an input curve with a profile proportional to that determined from the additional experiments. Local cerebral blood flow was calculated using this input curve, the local tissue concentration of tracer measured from the autoradiograms, and the blood-brain partition coefficient for iodoantipyrine (1.0 in the rat pup12).
Cerebral pathological change was assessed in animals anesthesia produced with 50 mg/kg pentobarbital, the brains were perfusion-fixed with 10% buffered formalin, removed, and placed in formalin for several days Results Local cerebral blood flow was reduced ipsilateral to the carotid artery ligation in the distribution of the middle cerebral artery territory in both vehicle-and dexamethasone-treated rats (Figure 1 ). There was a distinct regional distribution of the ischemia ipsilateral to the occlusion that corresponded closely to the regional distribution of brain damage observed in perfusion-fixed brains. The greatest reductions in cerebral blood flow occurred in the cortex and lateral parts of the striatum and thalamus, with the least marked reductions in flow occurring in structures closer to the midline.
Quantitative analysis of the autoradiograms demonstrated that blood flow at either 2 or 3 hours of hypoxia was similar in rats pretreated with vehicle or dexamethasone ( Figure 2 (Table 1) . Histological examination of the brains confirmed the marked neuroprotective effect of dexamethasone (e.g., Figure 1 ). The majority of vehicle-treated rats had areas of infarction or cellular necrosis ipsilateral to the occlu-LEFT SIDE -2 hr The present demonstration that local cerebral blood flow is similar in dexamethasone-and vehicle-treated animals is a crucial first step in better understanding the mechanism involved in dexamethasone's protection against brain damage due to hypoxia-ischemia. Rather than increasing cerebral perfusion via an effect on the systemic or cerebral circulations, dexamethasone treatment appears to act via another glucocorticoid-mediated effect that in some way alters susceptibility of the brain to hypoxic-ischemic damage.
Assessment of brain damage by visual inspection demonstrated that there was a high (91%) incidence of cerebral damage in vehicle-treated, control rats. This incidence of damage is similar to that observed previously by ourselves' and others9-1" with this neonatal model of hypoxia-ischemia. In contrast to the vehicletreated animals, rats treated with dexamethasone had no visual evidence of infarction, which is similar to our previous finding that dexamethasone administered 24 hours before hypoxia-ischemia prevents gross pathological damage in the cerebral cortex.' The present study also included a morphometric analysis of hematoxylin and eosin-stained sections clearly demonstrating that dexamethasone treatment results in a striking reduction in damage throughout the cerebrum. The relation between ischemia and cerebral pathology has been examined previously by others in this neonatal model of cerebral hypoxia. Originally, qualitative studies of cerebral blood flow demonstrated that the distribution of cerebral damage corresponded closely to a reduction in cerebral perfusion, suggesting that the injury observed is largely related to ischemia. 2 Subsequently, using quantitative autoradiographic methods, Vannucci et a13 and Ringel et al16 demonstrated a clear correlation between regions with the most severe blood flow reductions and those with the greatest sensitivity to pathological damage. In the present study, the distribution of damage also correlated well with the pattern of ischemia.
The results of several studies suggest that the level of ischemia is rather stable in this model of hypoxiaischemia. Silverstein et The present results also support the likelihood that blood pressure is similar in dexamethasone-and vehicle-treated animals. Clinical studies had indicated that hypertension may be an important side effect of dexamethasone treatment, particularly at the higher doses used to treat bronchopulmonary dysplasia (0.5 mg/kg/ day).45 However, the fact that heart rate is similar in vehicle-and dexamethasone-treated rats during hypoxia suggests that blood pressure may also be comparable in the two groups.' This is now further supported by the present demonstration of equivalent cerebral perfusion in the two treatment groups.
To conclude, an improvement in cerebral blood flow following dexamethasone administration does not account for the marked improvement in pathological outcome with dexamethasone treatment. Instead, dexamethasone must have another glucocorticoid-mediated effect that alters one or more of the biochemical processes in the brain involved in hypoxic-ischemic cell death. Since glucocorticoids have a large number of physiological and biochemical effects, there are many different potential mechanisms, several of which may ameliorate hypoxic-ischemic brain damage in the neonate. For example, hyperglycemia, which occurred in the dexamethasone-treated rats during hypoxia,' tends to exacerbate ischemic damage in adults but may be beneficial in young animals. [22] [23] [24] [25] As observed in the present study, dexamethasone also inhibits somatic growth, and studies by others suggest that growth retardation may either reduce brain damage caused by hypoxia-ischemia in neonatal rats26 or increase damage in growth-retarded newborn piglets.27 Irrespective of its overall physiological effect, dexamethasone likely binds to glucocorticoid receptors within the cell, and the hormone receptor complex then interacts with specific regulating DNA elements. This results in either positive or negative control of gene expression. Indeed, the fact that dexamethasone requires at least 3 hours to induce its effect' suggests that a minimum period of time is required, perhaps for the synthesis of some protein involved in the neuroprotective effect. Indeed, other studies have demonstrated that the beneficial effect of dexamethasone on cerebral edema is prevented by a blockade of de novo protein synthesis.28'29 Clearly, there are several possible ways in which dexamethasone may produce its novel neuroprotective effects, and further experiments are required to identify the mechanism involved.
